Close Menu

Personal Genome Diagnostics

N-of-One will provide clinical interpretation services for genomic tests conducted as part of the New England Veterans' Integrated Service Network oncology program

If the regional precision medicine program is successful, the VA might expand it for veterans around the country.

Personal Genome Diagnostics will supply its CancerSelect targeted gene panel to test veterans with newly diagnosed lung cancer.

The company plans to bring both tissue-based and blood-based targeted sequencing tests through FDA clearance.

Human Longevity will provide whole genome sequencing services to PGDx, which in turn will provide its cancer genome sequencing services to PGDx.

NEW YORK (GenomeWeb) – Appistry said today that it has signed a deal to include Personal Genome Diagnostics' CancerSelect panel in the recently released Appistry CloudDx genomics testing service.

NEW YORK (GenomeWeb News) – Cancer genome analysis firm Personal Genome Diagnostics today announced it raised $2.8 million in private funding in its first external financing round.

NEW YORK (GenomeWeb News) – Personal Genome Diagnostics today announced it has licensed the exclusive rights from Johns Hopkins University to a technology for analyzing cell-free tumor DNA circulating in blood.

NEW YORK (GenomeWeb News) – Personal Genome Diagnostics today announced a deal with MolecularMD to market personalized medicine services to oncology researchers and drug developers.

Pages

The US National Institutes of Health's All of Us project awarded $4.6 million to the company Color to develop a genetic counseling resource for the program.

The Times of India reports on a pilot study that used genomic testing to determine whether patients had drug-resistant tuberculosis.

New guidelines say that more women may benefit from genetic testing for hereditary breast or ovarian cancer, according to the Los Angeles Times.

In Cell this week: small proteins identified among human microbiome, role for tumor microbes in pancreatic cancer survival, and more.